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INTRODUCTION 
The incidence of diabetes in India is 3.8%34. It is well known that diabetes is 
a systemic disease, it affects almost all organ systems.Non-alcoholic fatty 
liver disease (NAFLD) is being increasingly recognized today as a 
potentially serious complication of diabetes, especially type 2. The spectrum 
of NAFLD extends from simple steatosis or steatosis with mild 
inflammation to severe non-alcoholic steatohepatitis (NASH). The 
pathophysiology and treatment remain unclear in many respects, but much 
progress has been made since the introduction of the terms non-alcoholic 
steatohepatitis (NASH) in 1980 and non-alcoholic fatty liver disease 
(NAFLD) in 1986. 1, 2 
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AIM 
The aim was to analyse the prevalence of fatty liver (non alcoholic fatty liver 
disease) in patients with diabetes. 
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                                    REVIEW OF LITERATURE 
 
THE ROLE OF LIVER IN GLUCOSE HOMEOSTASIS: 
 
The concentration of blood glucose is regulated within narrow limits. In the 
post absorptive state the concentration of blood glucose in individual 
humans and many mammals is set within the range of 4.5 – 5 mmol/L. After 
ingestion of a carbohydrate meal it may rise to 6.5 – 7.2 mmol/L. During 
fasting the levels fall to 3.3 – 3.9 mmol/L.3 
 
Blood glucose is derived from the diet, gluconeogenesis and glycogenolysis. 
Dietary carbohydrates that are actively digested contain glucose, galactose 
and fructose residues. These are transported to the liver via the portal vein. 
Galactose and fructose are readily converted to glucose by the liver. Glucose 
is formed from glucogenic compounds, which fall in two categories: 
1. those that involve direct net conversion to glucose without significant 
recycling such as amino acids and propionate. 
2. those which are products of partial metabolism of glucose in certain 
tissues and are converged to the liver and kidney to be resynthesised 
to glucose, Eg: lactic acid and glycerol 
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During starvation amino acids are transported from muscles (especially 
alanine)3 to liver for gluconeogenesis.  The energy required for the hepatic 
synthesis of glucose from pyruvate is derived from oxidation of fatty acids. 
 
Liver cells are fully permeable to glucose (via the GLUT 2 receptors) where 
as the cells of extra hepatic tissues except the pancreatic islets are relatively 
impermeable 3, therefore the passage through the cell membrane is the rate 
limiting step in the uptake of glucose in extra hepatic tissues. The 
concentration of glucose in the blood is an important factor that controls the 
rate of uptake in liver and extra hepatic tissues. It is probable that the activity 
of certain enzymes and concentration of key intermediates exert a direct 
effect on the uptake of glucose by the liver.3 
 
The enzyme glucokinase is important in regulating blood glucose after a 
meal. The enzymes hexokinase found in extra hepatic tissues is inhibited by 
glucose-6-phosphate, therefore some feedback control may be exerted on 
glucose uptake in extra hepatic tissues. The liver is not subject to this 
constraint because glucokinase is not affected by glucose-6-phosphate.3 
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At normal systemic blood glucose concentrations (4.5 – 5.5 mmol/L), the 
liver appears to be the net producer of glucose. However, as the glucose 
level rises the output of glucose ceases, so that at high levels there is net 
uptake of glucose. 3 
 
 
Insulin plays a central role in regulating blood glucose. It is produced by the 
B-cells of the islets of Langerhans in the pancreas as a direct response to the 
degree of hyperglycemia. The islet cell is freely permeable to glucose via the 
GLUT 2 receptors. Therefore, the blood glucose concentration determines 
the flux through glycolysis, the citric acid cycle and generation of ATP. 
Increased ATP concentration inhibits the ATP sensitive potassium channels 
causing depolarization of the B-cell membrane, which increases the calcium 
influx via voltage sensitive calcium channels stimulating exocytosis of 
insulin.4 
 
Other substances causing release of insulin from the pancreas include amino 
acids, free fatty acids, ketone bodies, glucagons, and secretin and 
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sulfonylurea drugs. Insulin increases glucose uptake in adipose tissue and 
muscle. 
 
 
There is no direct effect of insulin on glucose penetration of hepatic cells, 
however insulin does indirectly enhance long-term uptake of glucose by 
liver as a result of its actions on the synthesis of enzymes controlling 
glycolysis, glycogenesis and gluconeogenesis. 
 
 
Glucagon opposes the actions of insulin. It causes glycogenolysis by 
activating phosphorylase in the liver and it enhances gluconeogenesis from 
amino acids and lactate. Most of the endogenous glucagons and insulin are 
cleared from the circulation by the liver. Unlike adrenalin, glucagon does not 
have an effect of muscle phosphorylase. 
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Other hormones that increase blood glucose include: 
 
• ACTH 
• Growth Hormone – by decreasing glucose uptake in certain tissues 
and by mobilizing free fatty acids from adipose tissue which 
themselves inhibit glucose utilization. 
• Glucocorticoids -by increasing gluconeogenesis and by inhibiting 
utilization of glucose in extra hepatic tissues. 
• Epinephrine –by causing glycogenolysis in liver and muscle. 
• Thyroid hormone. 
 
The liver, kidney, intestine and platelets contain the enzyme glucose-6-
phosphatase which produces glucose from glucose-6-phosphate and is the 
final step in the production of glucose via gluconeogenesis. This enzyme 
is absent in other tissues. Glucose that is metabolized peripherally may 
therefore be converted back to glucose or hepatic glycogen via 
gluconeogenesis with lactate as primary substrate, this is known as Cori’s 
cycle. 
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In type 2 diabetes, excessive hepatic glucose output constitutes to the 
fasting hyperglycemia. Increased gluconeogenesis is the predominant 
mechanism responsible for this increased output, while glycogenolysis 
has not been shown to be increased in patients with type 2 diabetes.5 
 
  
 
LIVER DISEASE OCCURING AS A CONSEQUENCE OF DIABETES 
MELLITUS: 
 
GLYCOGEN DEPOSITION: 
 
Excess glycogen accumulation in the liver is seen in 80% of diabetic 
patients.6 Glycogen synthesis in the liver is impaired in diabetes due to 
defective activation in glycogen synthase. In patients with chronic diabetes, 
glycogen accumulation is seen and is postulated that long standing insulin 
deficiency may actually facilitate synthase activity. This and enhanced 
gluconeogenesis may account for the net accumulation of glycogen in 
diabetes. 
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The mechanisms of cytoplasmic glycogen deposition is uncertain but is 
perhaps related to the large variations in glucose concentration and frequent 
insulin dosing. Now correlation between hepatic glycogen content and 
fasting blood glucose levels has been demonstrated.7 It is postulated that 
glycogen is actually synthesized in the nucleus and has been found in 60 – 
75% of diabetic patients.8, 9 
 
 
The finding of glycogen nuclei in a patient with fatty liver is useful 
confirmatory evidence that fatty liver is secondary to diabetes even if the 
glucose tolerance test is normal. 
 
 
Patients showing solely excessive glycogen deposition may exhibit 
hepatomegaly and liver enzyme abnormalities and may have abdominal pain 
and vomiting and rarely ascites. All these abnormalities may improve with 
sustained glucose control.10 
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NON-ALCOHOLIC FATTY LIVER DISEASE: 
 
HISTORICAL PERSPECTIVE: 
 
Various types of fatty infilteration of the liver were classified by Virchow in 
the 1800s11. During this time the color shape and the firmness of fatty liver 
were described by pathologists and fat globules were proved to lie within the 
hepatic cells rather than the interstitium.12 
 
 
Zelman reported the existence of liver damage with fibrosis and early 
cirrhosis in obese patients without a significant history of alcohol 
consumption. This account resurfaced more recently in the case of patients 
who had undergone bypass surgery for morbid obesity. 13 – 18 
The association was widely attributed at that time to protein calorie 
malnutrition or intestinal bacterial overgrowth, although a correlation 
between obesity and diabetes and possible liver damage was not strongly 
emphasized. 
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DEFINITIONS AND TERMS: 
 
Non alcoholic fatty liver disease (NAFLD): 
 
Sometimes referred to as non alcoholic fatty liver. Indicates the presence of 
fatty infilteration of the liver defined as exceeding 5% weight and frequently 
taken as fat in >5% of hepatocytes. Includes non alcoholic steatohepatitis. 
 
 
Simple steatosis: 
 
A type of fatty infilteration (NAFLD) with no or minimal inflammation and 
no fibrosis. 
 
 
Non alcoholic steatohepatitis (NASH): 
 
A type of NAFLD with inflammation and fibrosis, usually beginning around 
the central vein and may progress to cirrhosis. 
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Primary NASH: 
 
This term is occasionally encountered in literature but not widely accepted. 
It indicates typical NASH associated with central obesity and often type 2 
DM, but without a specific, additional etiologic factor. The likelihood that 
many cases of secondary NASH represent unrecognized or exacerbated 
‘primary’ NASH makes the term less useful. 
 
 
Secondary NASH: 
 
NASH associated with a specific problem such as the effect of a drug or 
bariatric surgery. Many patients may have exacerbation of underlying 
NASH, making the distinction less useful. 
 
 
“Presumed” NASH or NAFLD: 
 
In several epidemiologic and pediatric studies, NASH has been used as 
presumptive diagnosis because of abnormal liver enzyme levels, negative 
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results of viral studies and echogenic or ‘bright’ liver at ultrasonography 
consistent with fatty infilteration. 
 
EPIDEMIOLOGY OF FATTY LIVER: 
 
NASH is one of the most common of all liver diseases. Obesity, type 2 
diabetes and hyperlipidemia have been the most constant conditions 
associated with steatosis and steatohepatitis and are predictors of more 
severe histologic disease.19 Diabetes was also identified as an independent 
risk factor for NASH.20 Hypertriglyceridemia is also identified as an 
independent predictor of steatosis at liver ultrasound imaging. 
 
 
Insulin resistance is common in NASH patients and hyperinsulinemia may 
play a pathogenic role in the progression of NASH, even in the absence of 
overt diabetes.21,22 It is estimated that as many as 75% of patients with type 2 
DM have fatty infilteration. Fatty infilteration also has been found to 
precede the development of overt diabetes. The progression to more overt 
diabetes in these patients may depend on additional factors such as 
peripheral fat metabolism, pancreatic islet cell vitality and the stage of liver 
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fibrosis. The severity of liver injury worsens with the degree of abnormal 
glucose metabolism in obese patients.24 
 
 
As mentioned earlier, hypertriglyceridemia been identified as a predictor 
both of steatosis at ultrasound examination and of more extensive fibrosis at 
biopsy in patients with NASH25. It is estimated that two thirds of patients 
with hypertriglyceridemia and one third of those with hypercholesterolemia 
have fatty liver.26 
 
 
NAFLD and NASH have been described in patients without the classic risk 
factors of obesity, diabetes and overt hyperlipidemia. This group appears to 
contain relatively younger men with milder histologic changes and with 
visceral or central adiposity and hyperinsulinemia.  
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CONDITIONS ASSOCIATED WITH NON-ALCOLHOLIC FATTY 
LIVER: 
 
Metabolic factors: 
 
• Obesity (truncal or central obesity) 
• Type 2 diabetes 
• Hyperlipidemia 
  
Specific conditions associated with fatty infilteration of liver: 
 
• Metabolic syndrome X 
• Lipodystrophy 
• Mitochondrial diseases 
• Weber Christian Disease 
 
Bariatric surgery: 
 
• Jejuno ileal bypass 
• Gastric bypass or gastroplasty 
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Medications: 
 
• Methotrexate 
• Amiodarone 
• Tamoxifen 
• Nucleoside analogues 
 
Parentral nutrition and malnutrition: 
 
• Total parentral nutrition 
• Kwashiokar 
• Celiac disease 
 
Miscellaneous: 
 
• Wilson’s disease 
• Toxins (carbon tetrachloride, per chloroethylene, phosphorous, ethyl 
bromide) 
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CLINICAL CRITERIA: 
 
By definition, the criteria for NASH requires exclusion of alcohol as an 
etiologic agent. Results of recent studies indicate that steatosis (possibly 
mediated by core protein metabolism) accelerates liver disease in patients 
with chronic hepatitis C. 
 
 
HISTOLOGIC CRITERIA: 
 
Steatosis, is defined as hepatic fat exceeding 5% total body weight and 
usually taken as fat identifiable in more than 5% of hepatocytes, is an 
essential feature of NAFLD. 
 
 
Within the spectrum of NAFLD, the term NASH indicates a more severe 
type of limb injury and worse prognosis than simple steatosis, which is 
differentiated by absence of inflammation or fibrosis and appears to have 
a long term stable course. 
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In the original description of NASH, Ludwig et al described the presence 
of diffuse or pericentral vein (perivenular) macrovesicular fat along with 
a mixed inflammatory infileterate (neutrophils and lymphocytes) in the 
perivenular area and associated with focal necrosis.1Other findings in 
NAFLD include glycogenated nuclei35,36 portal inflammation, 
microvesicular fat droplets and lipogranuloma.37,38 
 
 
 Accurate evaluation of fatty liver sample requires use of collagen stain      
(Masson trichrome) as well as eosin and hematoxylin.  
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CLASSIFICATION AND STAGES OF NAFLD AND NASH: 
 
CLASSES OF NAFLD:39 
 
Class I – Simple steatosis (no inflammation or absent fibrosis) 
 
Class II – Steatosis with lobular inflammation but absent fibrosis or  
                 balloon cells 
 
Class III – Steatosis plus inflammation and fibrosis of varying degrees 
 
Class IV – Steatosis, inflammation, fibrosis, balloon cells and Mallory  
                  Hyaline bodies 
 
FIBROSIS STAGES OF NASH: 40 
 
Stage I – Zone 3, pericentral vein, sinusoidal or pericellular fibrosis 
 
Stage II – Zone 3 sinusoidal fibrosis and zone 1 periportal fibrosis 
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Stage III – Bridging between zone 3 and zone 1 
 
Stage IV – regenerating nodules indicating cirrhosis 
 
 
CRYPTOGENIC CIRRHOSIS: 
  
Serial biopsy studies have established the progression of NASH to a 
stage of bland cirrhosis. The loss of fatty infilteration may be the result of 
altered blood flow or decreased sinusoidal permeability and lipoprotein 
delivery as the liver becomes fibrotic. Some nodules occasionally show 
focal fatty changes. 
 
 
FOCAL STEATOSIS AND FOCAL SPARING: 
 
In as series of patients with various forms of fatty liver disease detected 
radiographically, focal steatosis was evident in 15% and focal sparing 
(usually of the caudate lobe) seen in 9%.41 Variations in blood flow with 
resulting differences in insulin exposure and nutrient delivery is thought 
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to explain both focal sparing and focal steatosis.42,43  Histologic features 
of these lesions vary from simple steatosis to steatohepatitis. 
 
 
SYMPTOMS AND SIGNS: 
Most of the patients are asymptomatic. Fatigue is seen is approximately 
70% of the patients and right upper quadrant pain is seen in 50% of the 
patients. 
  
Hepatomegaly is usually caused by steatosis but can be caused by hepatic 
glycogenosis in diabetic patients.27 
  
Acanthosis nigricans is seen in some children with NASH.28  
The presence of palmar erythema or spider angiomas suggests the 
presence of cirrhosis. 
  
A family history of fatty liver, unexplained liver abnormalities or 
cryptogenic cirrhosis is present in approximately 20 – 25% of the cases.29 
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LABORATORY FINDINGS: 
 
Many patients have only abnormal liver function test as the initial 
manifestation of NASH. The aspartate transaminase and amino 
transaminase levels are elevated usually less than two times the upper 
limit of normal.12The level of AST, which is usually mitochondrial in 
origin is, correlates well with the extent of  histologic injury. The 
AST/ALT ratio also correlates with the extent of histologic injury, 
wherein ratio of greater than 1 often indicate the presence of fibrosis and 
ratio of less than 1 are consistent with mild disease. Gamma glutamyl 
transferase is also elevated and is usually less than 400IU/L.  
Patients with marked histologic changes may have normal enzyme levels. 
The use of certain anti diabetic medications usually thiazolidinedione 
medications, normalizes aminotransferase levels and improves the 
parameters of inflammation. 
 
  
Other lab abnormalities seen in NAFLD/NASH include abnormal 
sinusoidal deposition of immunoglobulin A. There is elevation of serum 
IgA and lowering of serum IgG/IgA ratio. The latter is associated with 
 23
more severe fibrosis. Anti nuclear antibodies are also found in about 25% 
of patients with NASH. Abnormal iron indices, including ferritin and 
transferrin saturation is present. 
 
 
Imaging of the liver has also been used to assess the distribution of body 
fat in comparison with anthropometric measurements. Computerised 
tomographic measurement of abdominal visceral fat at the L4-5 
intervertebral space, adjusted for age and sex is the most established 
technique. MRI and ultrasound have also been used to quantify body fat, 
especially central adiposity. 
 
 
 
Ultrasonography: 
  
In the liver, ultrasonography can detect the presence of hepatic steatosis 
by means of increased echogenicity and sound attenuation. The use of 
ultrasound as a screening tool for steatosis is limited because of the 
difficulty in differentiation steatosis from fatty infilteration, 
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misinterpretation of focal fatty sparing as a hypoechoic mass, and poor 
detection if the degree of steatosis is less than 30%. However for 
screening large population and in evaluation of pediatric patients for 
whom biopsy may be difficult, use of ultrasonography is common to 
diagnose ‘presumed’ NAFLD. 
 
 
 
Computerised Tomography: 
 
Unenhanced CT remains the optimal technique for imaging hepatic fat; 
the diagnosis depends on the attenuation differences between the liver 
and spleen. 
 
 
 
Magnetic Resonance Imaging and Spectroscopy: 
 
MRI has a less established role in imaging fatty liver. MR spectroscopy 
offers another means of assessing the degree of hepatic steatosis. It also 
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offers futuristic prospects of measuring metabolic parameters such as 
ATP levels in the liver and probably lipid peroxidation.  
 
 
 
PATHOGENESIS OF NON-ALCOHOLIC STEATOHEPATITIS: 
 
The development of NASH is likely to involve a ‘two hit’ mechanism in 
which the first hit is the development of steatosis (NAFL) and the second 
hit is the development of oxidative stress and lipid peroxidation (NASH). 
 
 
Hyperinsulinemia is the most common association with fatty liver. Levels 
of both triglycerides (unsaturated fatty acids) and free fatty acids (mostly 
saturated) are higher in the liver of obese patients than that of controls of 
normal weight. Elevation of free fatty acids may play a central role in 
both fat loading of the liver and in the development of insulin resistance 
through inhibition of glucose transport, inhibition of glycogen synthesis 
and stimulation of gluconeogenesis. 
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Insulin resistance is characterized by a reduced sensitivity to insulin in 
target tissues, especially liver, muscle and adipose tissue. The expected 
manifestations of insulin resistance include increased hepatic glucose 
output (normally suppressed by insulin), decreased peripheral (muscle) 
glucose utilization and enhanced lipolysis. Abnormal insulin homeostasis 
has been demonstrated in both NASH and NAFLD. Sanyal et al, 
suggested that the predominant site of resistance in NAFLD and NASH 
is the peripheral fat and skeletal muscle as opposed to the liver.31Factors 
that may promote insulin resistance in NAFLD include fatty acid 
metabolism, cytokine metabolism and genetic variables. 
 
 
Islet cell dysfunction is thought to be the turning point from latent 
hyperinsulinemia to the overt expression of diabetes in these patients. 
Although hyperinsulinemia in NAFLD is thought to potentiate liver 
disease through fat loading rather than to result from the liver problem. A 
similar feature of the islets to keep up with systemic needs may underlie 
the late development of overt diabetes in patients with NAFLD. 
 
 27
Lipid peroxidation reflects and imbalance between pro oxidant and anti 
oxidant substances (oxidative stress). It is a branching, chain reaction 
stimulated by a free radical attack on unsaturated fatty acids. Free 
radicals, which initiate the process, may be derived from mitochondrial, 
peroxisomal or cytochrome P450 fat metabolism with formation of 
superoxide, hydrogen peroxide and hydroxy radicals. The mitochondrion 
may be both an especially important source of reactive oxygen species 
and a target for injury resulting from lipid peroxidation. An additional 
source of injury in fatty liver may be endogenous production of ethanol 
caused by bacterial overgrowth.32 
 
 
Mitochondrial morphologic abnormalities i.e., swelling, loss of cristae 
and development of crystalline inclusions are found in NASH. Although 
there is evidence of mitochondrial dysfunction in NASH, fatty acid 
oxidation appears preserved, as does ketoacid decarboxylation. 
 
 
As in alcohol related liver disease, induction of CYP 2E1 in NASH, 
particularly in centrilobular distribution, has been described and may 
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further exacerbate oxidative stress and activation of cytokines. 
Microsomal CYP omega oxidation of fatty acids normally a minor 
pathway of fatty acid metabolism, may be a source of free radical 
generation in conditions of over abundant fat stores. 
 
 
Leptin is a circulating protein encoded by the obesity gene ( chromosome 
7q31) and is produced primarily in white adipose tissue. Leptin has an 
effect on insulin and peroxisome proliferator- activated receptor gamma 
activity and the levels increase in cirrhosis. The primary role of leptin is 
to govern the satiety through the action at the hypothalamus- however 
obesity among humans is typically associated with paradoxically elevated 
leptin levels. Leptin has been variably implicated in the development of 
histological injury in NAFL, however the idea still remains controversial. 
 
 
Elevation of cytokine levels, especially TNF alpha has been described 
occurring in NASH. Transformin Growth Factor Beta and interleukin 6 
have been implicated as mediators of fibrosis in NASH in some studies 
but not in others. It is possible that cytokine abnormalities are only 
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secondary to lipid peroxidation and are not primarily pathogenic. The 
increased expression of intercellular adhesion molecule 1, inducible nitric 
oxide synthase and endoglin in more histologically severe NASH 
supports at least a major secondary role of cytokine mediated injury. 
 
 
Peroxisomes are involved in numerous metabolic pathways, including 
synthesis of plasmalogens, bile acids, cholesterol and oxidation of very 
long chain fatty acids, branched chain fatty acids and dicarboxylic acids. 
Morphologic abnormalities with increased number but diminished size of 
microsomes have been found in fatty liver33. 
 
 
Peroxisomal fatty acid oxidation represents another potential source of 
reactive oxygen species, including superoxide and hydrogen peroxide, 
which form during peroxisomal oxidation of very long chain fatty acids 
and metabolism of dicarboxylic acids. 
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SECONDARY NON ALCOHOLIC STEATOHEPATITIS: 
 
BARIATRIC SURGERY: 
 
Weight reduction therapy played an important role in the recognition of 
NASH and NAFLD, owing to the unexpected exacerbation experienced 
by some patients after jejuno ileal bypass. Stimulation of TNF by 
bacterial endotoxin has been postulated as an etiologic factor.  
Micro nutrient deficiency has also been proposed as a cause. Despite its 
historical association with NASH, weight loss surgery, especially gastric 
bypass remains a viable option in the care of some patients. 
 
 
MEDICATION INDUCED CONDITIONS: 
 
A number of medications have been implicated as a cause of 
steatohepatitis. Diltiazem, methotrexate and tamoxifen produce a 
histologic picture similar to NASH. The risk factors for tamoxifen and 
methotrexate induced hepatitis are similar to that of NASH. This finding 
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suggests a possible synergistic effect the drug in a patient prone to 
NASH. 
 
Amiodarone has also been implicated as a cause of steatohepatitis. The 
use of amiodarone should not be undertaken without consideration of the 
high likelihood that many recipients have pre existing fatty liver because 
of shared risks between NASH and heart disease. 
 
Acquired lipodystrophy associated with insulin resistance and steatosis 
and sharing features with multiple symmetric lipomatosis has been 
described as part of nucleoside analogue therapy for HIV virus infection. 
The syndrome appears to be increased in women, may manifest itself 
acutely, and can be associated with Reye – syndrome like clinical 
features, neuropathy, myopathy and pancreatitis. Mitochondrial disease is 
thought to be the underlying cause of this disorder. 
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PARENTRAL NUTRITION AND MALNUTRITION: 
 
Liver disease, often with macrovesicular and microvesicular steatosis, is 
one of the most common and potentially severe side effects of total 
parentral nutrition. Phospholipidosis (fat laden cells in the sinusoidal 
space or portal tract) is also a common feature. Both the amount of lipid 
infusion and the composition appear to affect expression of liver disease 
in this setting. Choline deficiency probably plays a role in some patients. 
At the other end of the spectrum, fatty liver is a common finding in 
kwashiorkor, wherein export of lipid from the liver due to protein 
deficiency (diminished apoprotien B) is thought to be the primary 
mechanism. In both types of nutritional fatty liver, zone 1 (periportal) 
involvement may predominate. Potentially severe fatty infilteration of the 
liver can be seen in celiac disease and may be the presenting problem in 
this disease. 
 
 
 
 
 
 33
SOLVENTS AND INDUSTRIAL AGENTS: 
 
A variety of medications and some industrial solvents have been 
implicated in the development of fatty liver. Some of them include, 
carbon tetrachloride, dimethyl formamide and perchloroethylene. 
Elements such as phosphorous and certain compounds such as ethyl 
bromide and ethyl chloride have been implicated. Synergy between 
exposure to these agents and disease progression in an obese or diabetic 
patient is yet to be established. 
 
 
WILSON DISEASE: 
 
Macrovesicular and microvesicular steatosis is a well known feature of 
Wilson’s disease. It should be considered when a younger person has 
steatosis. Mitochondrial injury, mutations and premature oxidative aging 
have been described in patients with wilson’s disease. These findings 
suggest a possible overlap, through mitochondrial dysfunction, with more 
typical NAFLD and NASH. 
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INHERITED METABOLIC DISORDERS: 
 
Macro vesicular steatosis occurs in a variety of inherited metabolic 
diseases, most but not all, of which manifest themselves in childhood. 
Disorders include glycogen storage diseases, galactosemia, tyrosinemia, 
heterozygous hypobetalipoproteinemia and abetalipoproteinemia. The 
latter two disorders are characterized by impaired formation of very low 
density lipoproteins owing to decreased synthesis of apoprotein B. A 
number of lipid storage diseases such as cholesterol ester storage, 
Niemman pick’s disease, Tay – Sach’s disease and Gaucher’s disease, are 
associated with excessive fatty infilteration of the liver with cholesterol 
esters, sphingolipids, phospholipids, sphingomyelin, gangliosides or 
glucocerebrosides. Manifestation as systemic diseases in infancy and the 
distribution differentiate lipid storage disorders from typical NAFLD and  
NASH. 
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THERAPY FOR NON ALCOHOLIC STEATOHEPATITIS AND NON 
ALCOHOLIC FATTY LIVER DISEASE: 
 
 There is no proven therapy for NASH. Furthermore, the criteria for  
clearly indicating who should undergo more aggressive therapy is not 
well defined.  
 
 
Patients with simple steatosis probably need only observation with regard 
to liver disease, although associated conditions may warrant 
consideration of probable toxicity of common agents, such as, anti 
lipidemics, anti hypertensives, and anti diabetic medications. For patients 
with mild inflammation and no fibrosis, a less aggressive observational 
approach is required because the prognosis appears to be relatively good. 
A more directed therapy is required if fibrosis is present at biopsy. 
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DIETARY WEIGHT LOSS AND EXERCISE: 
 
The most practical and most commonly recommended therapy is 
exercise, diet and weight loss. Weight loss may be associated with 
progression of liver disease, especially if the rate of loss is more than 
1.6kg per week. It has been shown that the most effective conditioning 
exercise is that which just passes beyond the lactate threshold, a level 
usually associated with some degree of discomfort. Some studies have 
shown improvement in liver enzyme values, in histologic findings and 
degree of steatosis, however fibrosis was not significantly altered.44  
If patients were subjected to drastic calorie reduction for 10 to 28 days, 
then the histological findings worsened. 
 
 
WEIGHT REDUCTION SURGERY: 
 
Roux en y gastric bypass procedure remains a popular weight loss 
procedure for overweight persons even though it carries a risk for hepatic 
decompensation. In patients undergoing sustained weight loss after this 
procedure, the biological markers for syndrome X, such as, plasma 
 37
glucose, insulin, fibrinogen, triglyceride, uric acid and ALT levels, are 
usually reduced. Liver biopsy showed a significant reduction in steatosis 
but a slight overall increase in inflammation, there usually is no 
significant change in fibrosis. Although this treatment is often effective, 
caution is warranted with surgical procedures for weight reduction, 
owing to the risk of decompensation even with more limited procedures. 
 
 
 
URSODEOXYCHOLIC ACID AND CYTOPROTECTIVE AGENTS: 
 
The potential benefits of UDCA may be derived from effects on 
mitochondrial membrane stability, improvement in blood flow or 
immuno modulation. Therapy with UDCA may improve ALT levels and 
steatosis grades but no significant change in AST levels, inflammation or 
fibrosis. Taurine, an amino acid, also normalizes the liver enzyme values 
in children. 
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ANTI HYPERLIPIDEMIC AGENTS: 
 
Fibric acid derivatives have been used for hypertriglyceridemia. In 
general, their activity involves changes is lipoprotein metabolism, 
decreased delivery of free fatty acids to the liver, decreased release of 
VLDL from the liver, altered LDL metabolism and activation of PPAR α 
ligands. Treatment with gemfibrozil resulted in improvement in liver 
enzyme values. The over all effects of HMG Co A reductase inhibitors 
have not been well studied. 
 
 
   ANTI DIABETIC AGENTS: 
 
Insulin resistance appears to be crucial in most patients with NASH, 
therefore therapy aimed at hyperinsulinemia, insulin resistance or overt 
diabetes seems reasonable. 
 
 
Thiazolidinediones are ligands of PPAR γ that promote adipocyte 
differentiation. Use of these agents is associated with increased body 
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weight but decreased central adiposity, increased glucose transport and 
increased mitochondrial mass. They decrease the levels of some 
cytokines and inhibit inducible nitric oxide synthase. Troglitazone when 
used in the treatment of NASH, normalized liver enzyme values with no 
change in fibrosis. Troglitazone has shown benefit in the management of 
lipodystrophy. 
 
 
Another diabetic agent that warrants consideration is, metformin (a 
biguanide agent), which decreases steatosis and improves histological 
findings in NASH. Metformin stimulates aerobic metabolism and 
increases lactate production in pre adipocytes under experimental 
conditions. Lactic acidosis, however, appears to be rare. 
 
 
Acipimox is an inhibitor of lipolysis. It improves insulin sensitivity by 
lowering levels of free fatty acids. Its potential role in NASH is 
uncertain. 
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ANTI OXIDANTS AND NUTRITIONAL SUPPLEMENTS: 
 
Suppression of lipid peroxidation, TNF, and collagen gene expression 
have been reported with the use of vitamin E. 
N acetyl cysteine, which is converted to glutathione in the liver, improves 
liver enzyme values. 
 
Betaine, is a methyl donor in an alternative pathway for remethylation of 
homocysteine to methionine. S-adenosyl- methionine (SAMe) promotes 
conversion of phosphatidylethanolamine to phosphatidylcholine 
(lecithin), which promotes export of fat from the liver as VLDL. The use 
of this agent in NASH causes substantial improvement in biochemical 
values and relief of several histologic abnormalities, including steatosis, 
inflammation and fibrosis. 
 
Silymarin, the active component of milk thistle extract, is an over the 
counter drug that has been found to decrease the expression of CYP3A4 
and to decrease mitochondrial respiration in hepatocyte culture. 
Lazaroids, or 21 amino acid steroids, are anti oxidants. The above two 
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drugs have not been studied in the management of NASH but warrant 
consideration. 
 
 
LIVER TRANSPLANTATION: 
 
Transplantation in the care of advanced NASH often is complicated by 
the presence of co morbid conditions related to obesity, diabetes and 
hyperlipidemia. Recurrence of liver disease is another concern. Many 
reports have documented the recurrence of NASH and NAFLD after 
transplantation. 
 
Immunosuppression may play a role in the recurrence of NAFLD. 
Steroid therapy may promote fatty change and cyclosporine interacts 
with the mitochondrial transition pore, which regulates the 
electrochemical gradient across the mitochondrial membrane. 
 
Steatosis in donor livers is associated with relatively poor graft function. 
This likely reflects abnormal mitochondrial function and disturbed ATP 
homeostasis. Therefore pre operative liver biopsy on prospective donors 
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who are at high risk (increased BMI) is needed even if results of imaging 
studies are normal, in order to detect steatosis. 
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MATERIALS AND METHODS 
 
The study was conducted in Govt. Royapettah Hospital between March 2004 
to March 2007. The following are the patients’ inclusion and exclusion 
criteria: 
 
 
INCLUSION CRITERIA: 
 
1. Presence of diabetes mellitus (types 1 or 2) of any duration. 
 
EXCLUSION CRITERIA: 
 
1. Consumption of alcohol 
2. Seropositivity to HIV ELISA 
3. Seropositivity of anti HCV antibody 
4. Patients on drugs that are proven to cause steatohepatitis (steroids, 
amiodarone, oral contraceptive pills and other estrogen containing 
preparations. 
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A total of 75 diabetics(both type 1 and type 2) were studied during this 
period. Both inpatients and outpatients were included in the study. The 
study group consisted of  about 15 males and 60 females, between the 
age groups of 19 – 73 yrs, the average age being 51.88 yrs. The duration 
of diabetes in these patients ranged between 0 to 20 yrs, with the average 
duration being 5.17 yrs. 
  
All the above patients were screened for HIV and HCV and were 
negative for both. The following investigations were done on these 
patients: 
• Liver function test 
• Lipid profile 
• Ultrasound abdomen 
• Random blood sugar 
 
The patient’s weight and height were measured and BMI calculated. A 
BMI  >25 was considered overweight. 
 
Waist hip ratio was also measured to look for central obesity. 
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If the ultrasound showed evidence of fatty liver, with or without the 
elevation of transaminases, a presumptive diagnosis of NAFLD was 
made. 
 
The data were collected and analysed for the following: 
• Prevalence of NAFLD 
• Association between lipid profile and presence of NAFLD 
• Relationship between central obesity and NAFLD. 
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                                         RESULTS 
 
Among the 75 diabetics who were studied, fatty liver was found in 31 
patients (41.33%). 
  
No. of patients with fatty liver No. of patients without fatty liver 
31 (41.33%) 44 
 
 
 
The number of males with fatty liver were 2 (2.6%) and females 29(38.6%) 
 
Sex Fatty liver present Fatty liver absent 
Male 2 (2.6%) 13 
Female 29 (38.6%) 36 
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The number of patients with fatty liver who had central obesity (waist hip 
ratio >1) – 23 (74.19%). All the patients with fatty liver had central obesity 
(waist hip ratio >1 in males and >0.85 in females) 
 
Waist hip ratio >1 Waist hip ratio <1 
23 (74.19%) 8 (25.8%) 
 
 
 
The number of patients who had increased triglycerides >180 among 
patients with fatty liver 28 (90.3%) 
 
No. of patients with ↑ TGL  No. of patients with normal TGL 
28 (90.3%) 3 
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No. of patients who were overweight among the persons detected to have 
fatty liver – 21 (67.74%) 
No. of patients with normal BMI among the persons with fatty liver – 10 
(32.2%) 
 
No. of patients with BMI >25 No. of patients with BMI <25 
21 (67.74%) 10 (32.2%) 
 
 
 
 
No. of patients with increased cholesterol (>200 mg%) among patients with 
fatty liver – 20 (64.5%) 
 
Patients with cholesterol >200 Patients with cholesterol <200 
20 (64.5%) 11 (35.48%) 
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All the patients with ultrasound evidence of fatty liver showed, marginally 
elevated transaminases and occasionally of serum alkaline phosphatase. 
There was no alteration in the serum protein or albumin globulin ratio. 
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                                              DISCUSSION 
 
The prevalence of fatty liver in this study was found to be 41.3%. According 
to a study conducted by Daad H. Akbar, the prevalence of  NAFLD was 
found to be 55%.48According to another study conducted by Gupta P et al 
the prevalence of  NAFLD, by ultrasound examination, was found to be 
49%.46  
 
Among the patients with NAFLD the percentage of patients who were 
overweight was 67.74%. Wanless and Lentz found mild to severe steatosis 
in approximately 70% of obese patients and 35% of lean patients.20 
Garcia Monzon et al found NASH in 69% whereas 22% had simple steatosis  
and only 8% had normal biopsy findings.47In another study the presence of 
NAFLD was highest among obese patients, with BMI of 30 +/- 5.5 kg/m2.46                            
However, in another study there was no significant difference in body mass 
index among patients with NAFLD.48 
NASH can exist with only non specific symptoms for years in obese patients 
before manifesting itself either incidentally or with complications of 
cirrhosis or portal hypertension. 
 
 51
 
The prevalence of fatty liver was found to be higher among women (38.6%) 
than men. Many studies have found the presence of fatty liver to be higher in 
women.12,48 
 
NAFLD and NASH have been described in patients without the classic risk 
factors of obesity, diabetes and overt hyperlipidemia. It has been described 
in patients with central of visceral adiposity in a study conducted by Bacon 
BR et al.47 In another study, fatty liver was strongly correlated with visceral 
adipose tissue.48In this study the percentage of patients with central obesity 
among patients with fatty liver was 100% and those with a waist hip ratio of 
>1 was 74%. 
 
The no. of patients with increased triglycerides and cholesterol was found to 
be 90.3%  and 64.5% respectively. As mentioned earlier two thirds of 
patients with hypertriglyceridemia and one third of patients with 
hypercholesterolemia have fatty liver.26 In another study, among patients 
with obesity and fatty liver, approximately 20% have some type of 
previously identified hyperlipidemia.48 In other studies, fatty liver was 
strongly correlated with the degree of dyslipidemia, especially the level of 
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triglycerides. Hypertriglyceridemia was identified as an important risk factor 
in the development of NAFLD and NASH, it also correlates well with the 
histological severity of the disease.46,47,48 
 
In summary, obesity and type 2 diabetes are the best characterized risk 
factors, with older age and presence of hypertriglyceridemia, are predictors 
of the severity of underlying histologic changes. Many lean patients with 
fatty liver have truncal or central adiposity. The prevalence of NAFLD is 
more in women than men. Only 10% of consecutively examined obese 
patients have normal results at liver biopsy. Apporximately 5% have 
cirrhosis and 85% have steatosis. One third of the latter have NASH. 
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CONCLUSION 
 
• The prevalence of non-alcoholic fatty liver disease was  41.3% and it 
was present mainly in patients with type 2 diabetes mellitus. 
• It occurred more commonly in women (38.66%) than men. 
• The occurrence of non-alcoholic fatty liver was found to be higher in 
patients who were overweight/ obese and in those with central 
obesity. 
• 90.3% of the patients with fatty liver had dyslipidemias (especially 
hypertricglyceridemia. 
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PROFORMA 
NAME: 
 
AGE: 
 
SEX: 
 
OP/IP NO.: 
 
WEIGHT (IN KG): 
 
HEIGHT (IN CM): 
 
BODY MASS INDEX: 
 
WAIST (IN CM): 
 
HIP (IN CM): 
 
WAIST HIP RATIO: 
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DIAGNOSIS: 
 
DURATION OF DIABETES: 
 
DRUGS TAKEN BY THE PATIENT FOR  
DIABETES AND OTHER COMORBID 
CONDITIONS: 
 
LFT: 
 
LIPID PROFILE: 
 
ULTRASOUND ABDOMEN: 
 
KEY TO MASTER CHART 
 
• M Male 
• F Female 
• OP Out patient 
• IP In patient 
• BMI Body mass index 
• WHR Waist hip ratio 
• DM durn Diabetes mellitus duration 
• T.Bil Total bilirubin 
• AST Aspartate amino transferase 
• ALT Alanine amino transferase 
• SAP Serum alkaline phosphatase 
• T.Pro Total protein 
• T.Chol Total cholesterol 
• HDL High density lipoprotein 
• LDL Low density lipoprotein 
• VLDL Very low density lipoprotein 
• USG abd Ultrasonogram abdomen 
• RBS Random blood sugar 
• MF Metformin 
• G Glibenclamide 
• Gl Gliclazide 
• Gm Glimipride 
• CAD Coronary artery disease 
• CKD Chronic kidney disease 
• PT Pulmonary tuberculosis 
• Ch’it is Cholecystitis 
• COAD Chronic obstructive airway disease 
• Gbstone Gall bladder stone 
• CA brst Carcinoma breast 
• CVA Cerebro vascular accident 
• TIA Transient ischemic attack 
• Ren calc Renal Calculi 
• Fil scrotm Filarial scrotum 
• Ing hern Inguinal Hernia 
• Hyd’coele Hydrocoele 
• GUTB Genito urinary tuberculosis 
• DM Diabetes mellitus type 2 
• DM type 1 
  
Diabetes mellitus type 1 
 
AGE DISTRIBUTION
1%
1%
9%
35%
37%
13%
4%
10 to 20
21 to 30
31 to 40
41 to 50
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71 to 80
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Prevalence Of Fatty Liver
fatty liver
41%
no fatty liver
59%
 
 
 
Sex distribution in fatty liver
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Patients with Waist hip Ratio >1 in NAFLD
WHR >1
74%
WHR<1
26%
 
